With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the treatment journey for MS patients is varied and complex. To date, the MS market has accommodated a place for each therapy due to the disease’s heterogeneity, individualized treatment decisions, and a mix of positive and negative attributes that define each DMT. With every new launch, players in the MS space—both new and old—must assess where their products fit into the increasingly crowded market that will be increasingly affected by the presence of generics. Meanwhile, competing paradigms of escalation versus early intervention with high-efficacy drugs remain a source of debate. As such, patients’ journey through lines of therapy will continue to evolve. National patient-level claims data explore current DMTs’ position in newly diagnosed and recently treated patients and examine the line-of-therapy progression, including treatment duration and switch patterns and persistence and compliance by brand.
- What patient share do key brands garner by line of therapy in newly diagnosed MS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MS patients?
- How have newer entrants been integrated into the treatment algorithm?
- What proportion of MS patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What are the product-level compliance and persistency rates among drug-treated patients with MS?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand’s share.